Re-assessment of the IAB following joint referral from the Ministry of Health, the Social Security Directorate and the Directorate General for Health Services on 10 October 2013, in accordance with article R 163-19 of the French Social Security Code.
-
Clinical Benefit
Substantial
The actual benefit of NORMOSANG® is substantial.
Clinical Added Value
important
NORMOSANG, the only available medicinal product based on human hemin,provides a substantial improvement in actual benefit (Level II) in the treatment of severe acute attacks of hepatic porphyria.
Listen
